How should mexiletine be dosed and administered for ventricular arrhythmias and neuropathic pain, and what are its contraindications and monitoring requirements?

Mexiletine Dosing, Administration, and Monitoring

Mexiletine should be initiated at 200 mg every 8 hours with food or antacid, titrated by 50-100 mg increments every 2-3 days based on response, with most patients achieving control at 200-300 mg every 8 hours (maximum 1200 mg/day). 1

Dosing for Ventricular Arrhythmias

Standard Initiation

• Start with 200 mg every 8 hours when rapid arrhythmia control is not essential 1
• Always administer with food or antacid to reduce gastrointestinal side effects 1
• Allow minimum 2-3 days between dose adjustments 1

Dose Titration

• Adjust in 50-100 mg increments up or down based on clinical response 1
• Target dose: 200-300 mg every 8 hours achieves satisfactory control in most patients 1
• If inadequate response at 300 mg every 8 hours and patient tolerates well, may increase to 400 mg every 8 hours 1
• Maximum daily dose: 1200 mg/day (CNS side effects increase with higher doses) 1

Loading Dose Protocol

• When rapid control is essential: 400 mg loading dose, followed by 200 mg in 8 hours 1
• Therapeutic effect typically observed within 30 minutes to 2 hours 1

Alternative Q12H Dosing

• Patients stable on ≤300 mg every 8 hours may be converted to every 12-hour dosing for convenience 1
• Maximum 450 mg every 12 hours on this schedule 1
• Requires careful monitoring of arrhythmia suppression during conversion 1

Clinical Efficacy Data

Ventricular Arrhythmia Suppression

• Reduces premature ventricular contractions >50% in 72% of studies 2
• Reduces ventricular tachycardia >50% in 64% of studies 2
• Abolishes spontaneous or inducible VT/VF in 20-50% of patients with refractory arrhythmias 3
• Long-term arrhythmia suppression maintained in 57-80% of initial responders 3
• In chronic therapy, 69-80% of patients maintain ≥70% VPC suppression over 9 months 4

Special Populations - Long QT Syndrome Type 3

• In LQT3 patients with recurrent arrhythmias or ICD shocks, mexiletine shortens QTc and reduces recurrent arrhythmias 5
• Used as adjunctive therapy when beta-blockers alone are insufficient 5
• More effective in LQT1 and LQT3 than LQT2 5

Refractory Ventricular Tachycardia

• Effective in 30-50% of patients refractory to other antiarrhythmics 6
• Particularly useful after failed catheter ablation or when ablation is contraindicated 7
• Can be combined with amiodarone for enhanced efficacy in refractory cases 6, 7

Dosing for Neuropathic Pain

Off-Label Use

• Gradually titrate to maximum 750 mg/day in divided doses 8
• Produces statistically significant pain reduction (median pain scores from 7/10 to 4/10) 8
• Side effects are mild and well-tolerated at this dosage 8
• Consider when conventional pain medications have failed 8

Absolute Contraindications

Mexiletine is contraindicated in: 1

• Cardiogenic shock
• Preexisting second- or third-degree AV block without pacemaker

Dose Adjustments

Hepatic Impairment

• Patients with severe liver disease require lower doses and close monitoring 1
• Hepatic metabolism is the major elimination route 6

Cardiac Dysfunction

• Marked right-sided congestive heart failure reduces hepatic metabolism and necessitates dose reduction 1
• Unlike other antiarrhythmics, mexiletine has minimal hemodynamic effects and does not depress myocardial function 3, 6

Renal Impairment

• Patients with renal failure generally require usual doses (no adjustment needed) 1

Monitoring Requirements

Clinical Monitoring

• Clinical and electrocardiographic evaluation (including Holter monitoring) required to assess antiarrhythmic effect and guide titration 1
• Schedule Holter recordings at 3-month intervals during long-term therapy 4
• Monitor for arrhythmia suppression during dose changes 1

Electrocardiographic Effects

• Minimal effects on ECG intervals - does not prolong QRS or QT intervals (unlike quinidine) 3
• In LQT3 patients, produces desired QTc shortening 5, 2
• Blood tests and ECG intervals remain stable during long-term therapy 4

Drug Interactions

• Plasma levels affected by concomitant medications - monitor closely 1
• When combining with other antiarrhythmics (amiodarone, quinidine), enhanced efficacy but increased monitoring needed 6, 7

Adverse Effects Profile

Common Side Effects

• Gastrointestinal complaints occur in 33% of patients (most frequent adverse effect) 2
• CNS effects (neurological symptoms) are dose-dependent 1, 6
• Adverse effects warrant discontinuation in only 8-20% of patients 2, 4
• Most side effects are minor and controlled through dosage adjustment 3

Serious Adverse Events

• Low proarrhythmic potential compared to other antiarrhythmics 3
• Aggravation of arrhythmias uncommonly observed 6
• SAEs leading to discontinuation occur in approximately 14% of cases, mainly gastrointestinal or neurological 7

Transitioning from Other Antiarrhythmics

From Lidocaine

• Stop lidocaine infusion when first oral mexiletine dose is given 1
• Leave infusion line open until arrhythmia suppression is maintained 1
• Consider additive adverse effects (lidocaine and mexiletine have similar side effect profiles) 1

From Other Class I Agents

• Start mexiletine 200 mg at specified intervals after last dose: 1
  • 6-12 hours after quinidine sulfate
  • 3-6 hours after procainamide
  • 6-12 hours after disopyramide
  • 8-12 hours after tocainide
• Hospitalization recommended when withdrawal of previous agent may cause life-threatening arrhythmias 1

Key Clinical Pearls

• Most effective dosage range: 600-900 mg/day in divided doses 3, 6
• Elimination half-life approximately 10 hours (longer in acute MI, CHF, or hepatic insufficiency) 6
• Comparable efficacy to quinidine, procainamide, and disopyramide for chronic ventricular ectopy 3, 6
• In ischemic cardiomyopathy patients eligible for catheter ablation, mexiletine appears inferior to ablation but superior when ablation fails 7
• Particularly valuable in patients with complicating factors (acute MI, CHF) due to lack of adverse hemodynamic effects 3